Continuous Ambulatory Peritoneal Dialysis in Diabetic Patients

Transperitoneal transport in diabetic and non‐diabetic patients on peritoneal dialysis

“…The peritoneal transport capacity can be evaluated in different ways. Several studies have used peritoneal clearances to evaluate differences in transperitoneal transport capacity between diabetic and non‐diabetic patients ( Rottembourg et al ., 1983 ; Krediet et al ., 1986 a, b; Procaccini et al ., 1988 ; Querques et al ., 1989 ; Lee et al ., 1990 ; Scarpioni et al ., 1990 ; Lamb et al ., 1995 ; Serlie et al ., 1997 ). Clearances are calculated from the dialysate‐to‐plasma solute concentration ratio multiplied by the dialysate flow rate.…”

“…A detailed analysis of transperitoneal water transport includes estimation of ultra‐filtration rate and lymphatic flow rate. The ultra‐filtration capacity has evoked considerable interest ( Selgas et al ., 1988 ; Scarpioni et al ., 1990 ; Lamb et al ., 1995 ; Lin et al ., 1995b ; Serlie et al ., 1997 ), but to the best of our knowledge none have investigated differences in the lymphatic flow rate between diabetic and non‐diabetic patients on peritoneal dialysis.…”

“…The transport function of the peritoneal membrane in diabetic patients has evoked considerable interest ( Rottembourg et al ., 1983 ; Krediet et al ., 1986 a, b; Rubin et al ., 1986 ; Procaccini et al ., 1988 ; Selgas et al ., 1988 ; Querques et al ., 1989 ; Lee et al ., 1990 ; Scarpioni et al ., 1990 ; Wong et al ., 1994 ; Lamb et al ., 1995 ; Lin et al ., 1995a , b; Lin et al ., 1997 ; Serlie et al ., 1997 ). In the majority of these studies, no differences between diabetics and non‐diabetics on peritoneal dialysis were demonstrable ( Rottembourg et al ., 1983 ; Procaccini et al ., 1988 ; Selgas et al ., 1988 ; Querques et al ., 1989 ; Lee et al ., 1990 ; Wong et al ., 1994 ).…”

“…The ultra‐filtration capacity has been shown to be smaller among diabetics newly started on peritoneal dialysis ( Serlie et al ., 1997 ), but the majority of studies have not been able to show any differences between diabetics and non‐diabetics on peritoneal dialysis ( Selgas et al ., 1988 ; Scarpioni et al ., 1990 ; Lamb et al ., 1995 ; Lin et al ., 1995b ). One group found no differences in transport of solutes and water between patients with non‐insulin‐dependent diabetes mellitus (NIDDM) and patients with insulin‐dependent diabetes mellitus (IDDM) on peritoneal dialysis ( Lin et al ., 1995a , 1997).…”

Complications of Peritoneal Dialysis Part II

“…Statins and ezetimibe have proven efficacy in hyperlipidemia in PD patients. 101,102 Sevelamer, an oral phosphate binder, is also proven to improve lipid profiles. 103 Despite numerous studies demonstrating increased cardiovascular-related mortality associated with hyperlipidemia in PD patients, there is little evidence to support pharmacological treatment.…”